Trial record 1 of 1 for:
RLY-4008-101
REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04526106 |
|
Recruitment Status :
Active, not recruiting
First Posted : August 25, 2020
Last Update Posted : March 5, 2024
|
Sponsor:
Relay Therapeutics, Inc.
Information provided by (Responsible Party):
Relay Therapeutics, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | June 2024 |
| Estimated Study Completion Date : | October 2024 |